

A randomised controlled trial: two haemoglobin thresholds for transfusion in newborns less than 1000 g birth weight

Submission date 26/07/2007	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 26/07/2007	Overall study status Completed	☐ Protocol
Last Edited 08/06/2022	Condition category Pregnancy and Childbirth	☐ Statistical analysis plan
		☒ Results
		☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Haresh M. Kirpalani

Contact details

Room 3N11F
McMaster University Medical Center
1200 Main Street West
Hamilton, Ontario
Canada
L8N 3Z5
+1 905 521 2100 ext. 73024
kirpalan@mcmaster.ca

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00182390

Protocol serial number

MCT-41549 (follow-up trial PINTOS [started in 2002]: MCT-58455)

Study information

Scientific Title

A randomised controlled trial: two haemoglobin thresholds for transfusion in newborns less than 1000 g birth weight

Acronym

PINT (Preterms In Need of Transfusion)

Study objectives

A high haemoglobin threshold for transfusion in Extremely Low Birth Weight (ELBW) infants is associated with a lower rate of survival without severe morbidity (defined as one or more of retinopathy of prematurity, bronchopulmonary dysplasia, or periventricular leukomalacia /ventriculomegaly).

PINTOS: Neurodevelopmental outcome of extremely low birth weight infants randomised to high or low haemoglobin triggers for blood transfusion -
A follow up study was added to this trial in 2002 by Dr Whyte (all details pertaining to the follow up will be headed with the title 'PINTOS'). The hypothesis for this follow-up was that a low haemoglobin threshold as compared to a high haemoglobin threshold for transfusion in ELBW infants is associated with a lower rate of the combined outcome of death or, in survivors, the presence of cerebral palsy, cognitive delay, blindness or deafness at 18 - 21 months follow-up.

Please note that this trial was initially submitted for an ISRCTN in September 2005.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval was gained from the Research Ethics Boards:
For PINT: of McMaster University (Canada) on the 20th November 2002 (ref: #00-255).
For PINTOS: of IWK Health Centre, Halifax, NS, Canada, 14 July 2004 (ref: #2052).

Primary study design

Interventional

Study design

Multicentre, international, therapeutic management strategy randomised parallel, two arm trial, with outcome assessor and data analyst blinded.

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Anaemia of prematurity

Interventions

Transfusion at low haemoglobin threshold; blood transfusion with 15 ml/kg packed erythrocytes when the haemoglobin level, taken from capillary or central sites, falls to or below the following levels:

Group 1: Haemoglobin Threshold for Transfusion -

1. Week 1 (postnatal age):

1.1. Capillary sampling site: respiratory support: 115 g/l; not requiring respiratory support: 100 g/l

1.2. Central sampling site: respiratory support: 104 g/l; not requiring respiratory support: 90 g/l

2. Week 2 (postnatal age):

2.1. Capillary sampling site: respiratory support: 100 g/l; not requiring respiratory support: 85 g/l

2.2. Central sampling site: respiratory support: 90 g/l; not requiring respiratory support: 77 g/l

3. Greater than or equal to week 3 (postnatal age):

3.1. Capillary sampling site: respiratory support: 85 g/l; not requiring respiratory support: 75 g/l

3.2. Central sampling site: respiratory support: 77 g/l; not requiring respiratory support: 68 g/l

Group 2: Haemoglobin Threshold for Transfusion -

1. Week 1 (postnatal age):

1.1. Capillary sampling site: respiratory support: 135 g/l; not requiring respiratory support: 120 g/l

1.2. Central sampling site: respiratory support: 122 g/l; not requiring respiratory support: 109 g/l

2. Week 2 (postnatal age):

2.1. Capillary sampling site: respiratory support: 120 g/l; not requiring respiratory support: 100 g/l

2.2. Central sampling site: respiratory support: 109 g/l; not requiring respiratory support: 90 g/l

3. Greater than or equal to week 3 (postnatal age):

3.1. Capillary sampling site: respiratory support: 100 g/l; not requiring respiratory support: 85 g/l

3.2. Central sampling site: respiratory support: 90 g/l; not requiring respiratory support: 77 g/l

Alternative address for contact for PINT trial:

Dr. Haresh Kirpalani

University Pennsylvania, at Childrens Hospital of Philadelphia

Division Neonatology

34th Street & Civic Center

Philadelphia PA 19104

USA

Phone: +1 215 590 2455

Fax: +1 215 590 3051

Email: kirpalanih@email.chop.edu

Sponsor for PINTOS trial:

Dalhousie University (Canada)

c/o Carl Breckenridge, PhD

Vice President, Research

6299 South Street

Halifax, Nova Scotia

B3H 4H6

Canada

Tel: +1 902 494 2211

Fax: +1 902 494 2319

Contact for PINTOS trial:

Dr Robin K Whyte

IWK Health Centre

5980 University Avenue

Halifax, Nova Scotia
B3J 6R8
Canada
Tel: +1 902 470 7426
Fax: +1 902 470 6469
Email: robin.whyte@dal.ca

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Survival to tertiary hospital discharge without severe morbidity (one or all of bronchopulmonary dysplasia, retinopathy of prematurity Grade 3 - 4, periventricular leukomalacia/ventriculomegaly present on ultra-sound scans) at corrected age 40 weeks.

PINTOS:

Composite outcome of death or the presence of cerebral palsy, cognitive delay, blindness or deafness measured at or during 24 months.

Key secondary outcome(s)

1. Growth in weight and head circumference
2. Time to extubation, by discharge from hospital
3. Time on oxygen, by discharge from hospital
4. Length of hospital stay until discharge home
5. Incidences of necrotising enterocolitis
6. Apnoea requiring treatment
7. Number of infections
8. Use of post-natal steroids
9. Intraventricular haemorrhage Grade 4 or with hydrocephalus
10. Mean levels of haemoglobin
11. Number of transfusions
12. Number of donor exposures

Time point of measurement: at discharge from hospital or at corrected age of 40 weeks.

PINTOS:

1. Vineland Communication score
2. Vineland Daily Living score
3. Vineland Socialisation score
4. Vineland Motor Skills score
5. Gross Motor Function Classification System Levels
6. Weight
7. Length
8. Head Circumference
9. Haemoglobin
10. Haematocrit

- 11. Mean Corpuscular Haemoglobin
- 12. Mean Cell Volume
- 13. Ferritin

Time point of measurement: 18 - 21 months corrected gestational age.

Completion date

15/09/2005

Eligibility

Key inclusion criteria

- 1. Infants of birth weight less than 1000 g, either sex
- 2. Postnatal age less than 48 hours
- 3. No transfusion beyond first six hours of life
- 4. Estimated gestational age of 30 completed weeks or less

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Neonate

Sex

All

Key exclusion criteria

- 1. Infant considered non-viable by attending physician
- 2. Infant has cyanotic congenital heart disease
- 3. Infant's parents known to be opposed to blood transfusion
- 4. Either parent has haemoglobinopathies or congenital anaemias
- 5. Infant has haemolytic disease
- 6. Infant has severe acute haemorrhage, severe shock, severe sepsis with coagulopathy or requires peri-operative transfusion
- 7. Prior treatment with or intention to treat with erythropoietin

Date of first enrolment

04/02/2001

Date of final enrolment

15/09/2005

Locations

Countries of recruitment

Australia

Canada

United States of America

Study participating centre

Room 3N11F

Hamilton, Ontario

Canada

L8N 3Z5

Sponsor information

Organisation

McMaster University (Canada)

ROR

<https://ror.org/02fa3aq29>

Funder(s)

Funder type

Research organisation

Funder Name

Canadian Institutes of Health Research (CIHR) (Canada) - <http://www.cihr.irsc.gc.ca> (ref: PINT: MCT-41549/PINTOS: MCT-58455)

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		01/09/2006		Yes	No
Other publications	follow up study	01/01/2009	08/06/2022	Yes	No